《新股表现》京东健康(06618.HK)续升8%高见134.4元再破顶
内地最大线上医疗健康平台及线上零售药房--京东健康(06618.HK)上市第五天,股价均反覆造好,今天更升破首挂日盘中所创高位123.9元,最高见134.4元,现造131.8元,续升8%,成交增至1,754万股,涉资22.61亿元。
MSCI及富时罗素将分别於本月22日及21日起正式将京东健康纳入MSCI标准指数/大盘股指数及富时香港指数。另外,恒指公司将於本月22日起将京东健康纳入恒生综合指数、恒生中国企业指数、恒生科技指数、恒生医疗保健指数及恒生港股通新经济指数。摩通料京东健康获纳入上述指数後,合计流入被动资金达5.74亿美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.